content_image/96813.jpg content_image/96817.jpg
<img src='content_image/96813.jpg'>

## Financial Contents 

The following table sets forth selected financial informa- tion with respect to Edwards Lifesciences. The information set forth below should be read in conjunction with Edwards Lifesciences’ “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Consolidated Financial Statements” found elsewhere in this Annual Report to Shareholders. No per share data for 

<img src='content_image/96817.jpg'>

(a) See Note 3 to the “Consolidated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for additional information regarding non-recurring charges of $ 83 million and $ 330 million during 2001 and 2000 , respectively. Additionally, during 1997 , the Company recorded a $ 132 million in-process research and development charge relating to the acquisition of Research Medical, Inc. 

(b) The results prior to April 1 , 2000 present Edwards Lifesciences on a divisional basis as it had historically been operated as part of Baxter. Subsequent to the Distribution, Edwards Lifesciences’ Japan operations are presented on an equity basis as opposed to the consolidation method reflected in the historical results. As such, certain of the results reflected here are not comparable to the presentation subsequent to the Distribution. See Note 1 to the “Consolidated Financial Statements.” 

(c) See Note 3 to the “Consolidated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for additional information regarding the write-off of goodwill of $ 80 million and $ 282 million during 2001 and 2000 , respectively. 

## Selected Financial Data 

the years 2000 and prior have been presented because Edwards Lifesciences’ earnings were part of Baxter’s earnings through the close of business on March 31 , 2000 . See Note 3 to the “Consolidated Financial Statements” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for discussions of the effect of certain asset divestitures on Edwards Lifesciences’ operations. 

